Literature DB >> 33510770

Genetic Markers for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in the Asian Indian Population: Implications on Prevention.

Swapna S Shanbhag1, Madhuri A Koduri2,3, Chitra Kannabiran2,4, Pragnya R Donthineni1, Vivek Singh2,5, Sayan Basu1,2,5.   

Abstract

This review attempts to collate all the studies performed in India or comprising a population originating from India and to find out if there is an association between the HLA (human leucocyte antigen) type of individual and development of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) subsequent to medication use. The authors performed a PubMed search of all articles published in English from 2009 to 2019 for articles that studied HLA type in patients who developed SJS/TEN after intake of a specific drug in the Asian Indian population or in individuals of Asian Indian origin. The selection criteria were satisfied by a total of 11 studies that reported HLA associations with specific drugs, which induced SJS/TEN, mainly anti-epileptic drugs, and cold medicine/non-steroidal anti-inflammatory drugs. These studies involved a small number of patients, and hence, there is limited evidence to conclude if these associations can be extrapolated to a larger population of the same ethnicity. Similar multi-center studies need to be conducted with a larger sample size to confirm these associations. This would have implications in policy making and for understanding the potential of using genetic markers as a screening tool before prescribing a drug to a patient, which might make them susceptible to developing a potentially life-threatening disease such as SJS/TEN. This is possibly the only mode of primary prevention for this potentially fatal severe cutaneous adverse drug reaction.
Copyright © 2021 Shanbhag, Koduri, Kannabiran, Donthineni, Singh and Basu.

Entities:  

Keywords:  India; Stevens-Johnson Syndrome; anti-epileptics; carbamazepine; genetic markers; human leucocyte antigen; severe cutaneous adverse drug reaction; toxic epidermal necrolysis

Year:  2021        PMID: 33510770      PMCID: PMC7837290          DOI: 10.3389/fgene.2020.607532

Source DB:  PubMed          Journal:  Front Genet        ISSN: 1664-8021            Impact factor:   4.599


  82 in total

1.  Real-world cost-effectiveness of pharmacogenetic screening for epilepsy treatment.

Authors:  Zhibin Chen; Danny Liew; Patrick Kwan
Journal:  Neurology       Date:  2016-02-17       Impact factor: 9.910

Review 2.  Chronic lung disease following Stevens-Johnson syndrome.

Authors:  M Basker; T Cherian; P Raghupathy
Journal:  Indian Pediatr       Date:  1997-09       Impact factor: 1.411

Review 3.  Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up.

Authors:  H Y Lee; S A Walsh; D Creamer
Journal:  Br J Dermatol       Date:  2017-09-22       Impact factor: 9.302

4.  Chronic Ocular Sequelae of Stevens-Johnson Syndrome in Children: Long-term Impact of Appropriate Therapy on Natural History of Disease.

Authors:  Sayan Basu; Swapna S Shanbhag; Arjun Gokani; Richa Kedar; Chirag Bahuguna; Virender S Sangwan
Journal:  Am J Ophthalmol       Date:  2018-02-06       Impact factor: 5.258

5.  ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis.

Authors:  B Sassolas; C Haddad; M Mockenhaupt; A Dunant; Y Liss; K Bork; U F Haustein; D Vieluf; J C Roujeau; H Le Louet
Journal:  Clin Pharmacol Ther       Date:  2010-04-07       Impact factor: 6.875

6.  Limbal Stem Cell Deficiency-Demography and Underlying Causes.

Authors:  Jayesh Vazirani; Dhanyasree Nair; Swapna Shanbhag; Siva Wurity; Abhishek Ranjan; Virender Sangwan
Journal:  Am J Ophthalmol       Date:  2018-01-31       Impact factor: 5.258

Review 7.  Acute and Chronic Ophthalmic Involvement in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis - A Comprehensive Review and Guide to Therapy. II. Ophthalmic Disease.

Authors:  Sahar Kohanim; Sotiria Palioura; Hajirah N Saeed; Esen K Akpek; Guillermo Amescua; Sayan Basu; Preston H Blomquist; Charles S Bouchard; John K Dart; Xiaowu Gai; José A P Gomes; Darren G Gregory; Geetha Iyer; Deborah S Jacobs; Anthony J Johnson; Shigeru Kinoshita; Iason S Mantagos; Jodhbir S Mehta; Victor L Perez; Stephen C Pflugfelder; Virender S Sangwan; Kimberly C Sippel; Chie Sotozono; Bhaskar Srinivasan; Donald T H Tan; Radhika Tandon; Scheffer C G Tseng; Mayumi Ueta; James Chodosh
Journal:  Ocul Surf       Date:  2016-02-13       Impact factor: 5.033

Review 8.  An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methods.

Authors:  J P Kelly; A Auquier; B Rzany; L Naldi; S Bastuji-Garin; O Correia; S Shapiro; D W Kaufman
Journal:  J Clin Epidemiol       Date:  1995-09       Impact factor: 6.437

Review 9.  Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis.

Authors:  Ratchadaporn Somkrua; Elizabeth E Eickman; Surasak Saokaew; Manupat Lohitnavy; Nathorn Chaiyakunapruk
Journal:  BMC Med Genet       Date:  2011-09-09       Impact factor: 2.103

Review 10.  Multidisciplinary care in Stevens-Johnson syndrome.

Authors:  Swapna S Shanbhag; James Chodosh; Cherie Fathy; Jeremy Goverman; Caroline Mitchell; Hajirah N Saeed
Journal:  Ther Adv Chronic Dis       Date:  2020-04-28       Impact factor: 5.091

View more
  1 in total

Review 1.  Differential expression of tear film cytokines in Stevens-Johnson syndrome patients and comparative review of literature.

Authors:  Madhuri Amulya Koduri; Deeksha Prasad; Shriya Upadhyaya; Jilu Jaffet; Swapna S Shanbhag; Sayan Basu; Vivek Singh
Journal:  Sci Rep       Date:  2021-09-16       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.